72 related articles for article (PubMed ID: 17077279)
1. Rosiglitazone inhibits mouse liver regeneration.
Turmelle YP; Shikapwashya O; Tu S; Hruz PW; Yan Q; Rudnick DA
FASEB J; 2006 Dec; 20(14):2609-11. PubMed ID: 17077279
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
[TBL] [Abstract][Full Text] [Related]
6. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
Yamamoto Y; Ono T; Dhar DK; Yamanoi A; Tachibana M; Tanaka T; Nagasue N
J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
[TBL] [Abstract][Full Text] [Related]
7. Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A.
Chen L; Zeng Y; Yang H; Lee TD; French SW; Corrales FJ; García-Trevijano ER; Avila MA; Mato JM; Lu SC
FASEB J; 2004 May; 18(7):914-6. PubMed ID: 15033934
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway.
Yang Q; Chen C; Wu S; Zhang Y; Mao X; Wang W
Eur J Pharmacol; 2010 Dec; 649(1-3):108-14. PubMed ID: 20863825
[TBL] [Abstract][Full Text] [Related]
9. Differential lymphotoxin-beta and interferon gamma signaling during mouse liver regeneration induced by chronic and acute injury.
Akhurst B; Matthews V; Husk K; Smyth MJ; Abraham LJ; Yeoh GC
Hepatology; 2005 Feb; 41(2):327-35. PubMed ID: 15660390
[TBL] [Abstract][Full Text] [Related]
10. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.
He G; Muga S; Thuillier P; Lubet RA; Fischer SM
Mol Carcinog; 2005 Aug; 43(4):198-206. PubMed ID: 15864802
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation.
Kakiuchi-Kiyota S; Arnold LL; Yokohira M; Koza-Taylor P; Suzuki S; Varney M; Pennington KL; Cohen SM
Toxicol Pathol; 2011 Dec; 39(7):1032-45. PubMed ID: 21937740
[TBL] [Abstract][Full Text] [Related]
12. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
Coyle AT; Kinsella BT
Biochem Pharmacol; 2006 Apr; 71(9):1308-23. PubMed ID: 16499875
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
14. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A.
Olsen H; Haldosén LA
Exp Cell Res; 2006 May; 312(8):1371-80. PubMed ID: 16457814
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.
Aoyama T; Ikejima K; Kon K; Okumura K; Arai K; Watanabe S
Hepatology; 2009 May; 49(5):1636-44. PubMed ID: 19205029
[TBL] [Abstract][Full Text] [Related]
17. The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development.
Takahashi Y; Hasegawa-Moriyama M; Sakurai T; Inada E
Anesth Analg; 2011 Aug; 113(2):398-404. PubMed ID: 21490083
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the role of hepatic PPARγ expression during mouse liver regeneration.
Gazit V; Huang J; Weymann A; Rudnick DA
Hepatology; 2012 Oct; 56(4):1489-98. PubMed ID: 22707117
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species derived from NADPH oxidase system is not essential for liver regeneration after partial hepatectomy.
Ueno S; Campbell J; Fausto N
J Surg Res; 2006 Dec; 136(2):260-5. PubMed ID: 17046793
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
